中国结合医学杂志（英文版）Chinese Journal of Integrative Medicine

Home

Chinese Version

Online office

Journal Online

Forthcoming Articles

Current Issue

Next Issue

Earlier Issues

Download

Editorial Board [2019/7/26]

Instructions for Authors [2015/1/26]

Instructions to Contributors [2013/3/25]

Top

Top Downloaded
Top Cited

Links

alljournals

扫描微信二维码，获取更多信息

Effects of Hedan Tablet (荷丹片) on Lipid Profile, Proprotein Convertase Subtilisin/Kexin Type 9 and High-Density Lipoprotein Subfractions in Patients with Hyperlipidemia: A Primary Study

View Full Text View/Add Comment Download reader

KeyWord:Hedan Tablet, hyperlipidemia, lipid profile, proprotein convertase subtilisin/kexin type 9, high-density lipoprotein subfraction, Chinese medicine

Author Name	Affiliation	E-mail
XU Rui-xia, WU Na-qiong, LI Sha
LI Jian-jun	Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (100037), China	lijianjun938@yahoo.com

Hits: 1054

Download times: 0

Abstract:

Objective: To investigate the effects of Hedan Tablet (荷丹片) on serum lipid profile, proprotein convertase subtilisin/kexin type 9 (PSCK9) and high-density lipoprotein (HDL) subfractions in patients with hyperlipidemia. Methods: Thirty-seven patients with hyperlipidemia were randomized to treatment with Hedan Tablet 4.38 g/day as Hedan group (18 cases) or placebo (19 cases) as control group for 8 weeks. The lipid profile, PCSK9 and HDL subfractions were determined at day 0 and week 8 in both groups respectively. Results: Hedan treatment for 8 weeks mildly decreased serum low-density lipoprotein cholesterol (LDL-C) levels, while no changes were found in total cholesterol (TC), triglycerides (TG) and PCSK9 concentrations. Furthermore, Hedan treatment increased the concentration of large high-density lipoprotein cholesterol (HDL-C) and the percentage of large HDL subfraction, while decreased the concentration of small HDL-C and the percentage of small HDL subfraction without changing serum HDL-C levels in patients with hyperlipidemia. Conclusion: Hedan treatment of 4.38 g per day for 8 weeks could confer a favorable effects on serum LDL-C concentration as well as HDL subfractions.